CJC-1295

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) that binds to growth hormone secretagogue receptors. It stimulates sustained growth hormone release for up to 7 days, promoting muscle growth and fat metabolism.

Category: Compound Evidence: 6/10 Tier: Tier 3 (preliminary)

Origin & History

CJC-1295 is a synthetic peptide that acts as a growth hormone-releasing hormone (GHRH) analog. It is produced through peptide synthesis and is used for its potential to increase growth hormone levels.

Historical & Cultural Context

Developed in the early 2000s, CJC-1295 is used in research for its potential anti-aging and performance-enhancing effects.

Health Benefits

- Stimulates sustained release of growth hormone (GH), promoting continuous muscle growth and fat metabolism. - Enhances muscle mass and strength by increasing protein synthesis and reducing muscle catabolism. - Supports fat loss by boosting lipolysis and metabolic rate, aiding in body composition improvements. - Improves sleep quality, which is vital for hormone regulation and tissue repair. - Increases cellular regeneration and repair, accelerating recovery from exercise and injury. - Promotes bone density and joint health by stimulating osteoblast activity. - May improve skin elasticity and reduce signs of aging through increased collagen production. - Offers long-acting effects with a single weekly dose, making it convenient for busy lifestyles.

How It Works

CJC-1295 binds to growth hormone secretagogue receptors (GHSR) in the anterior pituitary gland, triggering cyclic adenosine monophosphate (cAMP) signaling pathways. This stimulates somatotroph cells to release growth hormone in pulsatile patterns. The peptide's lysine modification allows it to bind to albumin, extending its half-life to approximately 6-8 days compared to natural GHRH's 7-minute half-life.

Scientific Research

CJC-1295 has been studied in animal models and early human trials, showing potential for sustained growth hormone release. Further research is required.

Clinical Summary

Limited human studies exist for CJC-1295, with most research conducted on small cohorts of 10-20 participants. One study in healthy adults showed 2-10 fold increases in growth hormone levels lasting up to 6 days after injection. Animal studies demonstrate improved body composition with increased lean mass and reduced fat mass over 4-8 week periods. However, long-term safety data and large-scale clinical trials are lacking, limiting evidence quality.

Nutritional Profile

- Composed of a sequence of amino acids.
- Administered via subcutaneous injection.
- Long-acting due to its ability to bind to albumin.

Preparation & Dosage

Typical dosage ranges from 1 mg to 2 mg per week, administered via subcutaneous injection. Consult a healthcare provider before use.

Synergy & Pairings

GHRP-2, L-Glutamine, Arginine

Safety & Interactions

Common side effects include injection site reactions, headaches, dizziness, and potential water retention. CJC-1295 may interact with diabetes medications by affecting glucose metabolism and insulin sensitivity. It's contraindicated in individuals with active cancer due to growth hormone's potential tumor-promoting effects. Safety during pregnancy and breastfeeding is unknown, and the peptide should be avoided in these populations.